文献速递乳腺癌放疗

接受放射治疗与曲妥珠单抗治疗的HER-2阳性乳腺癌患者心脏毒性评估

Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-01-02

本研究为HERA试验的回顾性分析,纳入3321例接受曲妥珠单抗治疗的HER-2阳性乳腺癌患者,中位随访11年,比较左侧放疗、右侧放疗与未放疗三组的心脏毒性。结果显示三组左心室射血分数下降发生率及心血管事件发生率均无显著差异,提示放疗未显著增加心脏毒性风险。

要点

  • 左侧放疗组、右侧放疗组与未放疗组的左心室射血分数下降发生率分别为9.18%、8.99%、8.80%,无显著差异(P = .073)。
  • 心血管事件发生率三组均较低,未放疗组0.62%、右侧放疗组0.92%、左侧放疗组1.08%,无显著差异(P = .619)。
  • 单因素和多因素竞争风险回归显示,左侧或右侧放疗均未显著增加左心室射血分数下降或心血管事件的风险。

核心结论

  • 对HERA试验的分析提示,在接受曲妥珠单抗治疗的HER-2阳性乳腺癌患者中,放疗未显著增加心脏毒性风险。
  • 需要继续监测患者,以研究当代乳腺癌治疗的晚期效应。

研究设计与样本

  • 本研究为对HERA试验(一项确立曲妥珠单抗在HER-2阳性乳腺癌中疗效的3期前瞻性随机临床试验)的回顾性分析。
  • 共纳入3321例接受曲妥珠单抗治疗(伴或不伴放疗)的试验患者,中位随访11年,密切监测心脏功能。
  • 主要终点为确定放疗对左心室射血分数(LVEF)及心血管事件发生的影响。

主要发现

  • 患者分为3组:组1为1270例接受曲妥珠单抗和左侧放疗;组2为1271例接受曲妥珠单抗和右侧放疗;组3为780例接受曲妥珠单抗而未接受放疗。
  • 超声心动图记录的LVEF下降发生率分别为9.18%、8.99%和8.80%,三组间无显著差异(P = .073)。
  • 心血管事件发生率在所有组中均较低,组3最低(0.62%),其次为组2(0.92%)和组1(1.08%)(P = .619)。
  • 单因素和多因素竞争风险回归显示,左侧和右侧放疗均未显著增加LVEF下降或心血管事件的风险。

局限性

  • 需要继续监测患者,以研究当代乳腺癌治疗的晚期效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Trastuzumab is associated with cardiac dysfunction in patients with human epidermal growth factor receptor 2 (HER-2)-positive breast cancer. The current study examines the effect of radiation therapy (RT) on cardiotoxicity in this patient population. METHODS AND MATERIALS: The Herceptin Adjuvant (HERA) trial is a phase 3 prospective, randomized clinical trial that established the efficacy of trastuzumab in HER-2-positive breast cancer. The current study is a retrospective analysis of 3321 trial patients treated with trastuzumab, with or without RT. Cardiac function was closely monitored over a median follow-up period of 11 years. The primary endpoint of the current study was to determine the effect of RT on left ventricular ejection fraction (LVEF) and the occurrence of cardiovascular events. RESULTS: Patients were divided into 3 groups: 1270 patients received trastuzumab and left-sided RT (group 1); 1271 patients received trastuzumab and right-sided RT (group 2); and 780 patients received trastuzumab with no RT (group 3). The incidence of decline in LVEF documented by echocardiography was 9.18%, 8.99%, and 8.80%, respectively, with no significant differences among the 3 groups (P = .073). The incidence of cardiovascular events was low in all groups, with the lowest incidence noted in group 3 (0.62%) followed by group 2 (0.92%) and group 1 (1.08%) (P = .619). Univariate and multivariate competing-risks regression showed that left-sided and right-sided RT delivery did not significantly increase the risk of LVEF decline or cardiovascular events. CONCLUSIONS: Our analysis of the HERA trial suggests that RT does not significantly increase the risk of cardiotoxicity in HER-2-positive breast cancer patients treated with trastuzumab. Continued monitoring of patients is needed to investigate late effects of contemporary treatments for breast cancer patients.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Bachir B, Anouti S, Abi Jaoude J, et al. Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab. Int J Radiat Oncol Biol Phys. 2022. PMID: 34986381. doi:10.1016/j.ijrobp.2021.12.159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。